| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Pharvaris N.V. (NASDAQ: PHVS) is a clinical-stage biopharmaceutical company pioneering novel therapies for rare diseases, with a primary focus on hereditary angioedema (HAE). Headquartered in Leiden, the Netherlands, Pharvaris leverages its expertise in bradykinin B2-receptor antagonism to develop innovative treatments, including PHA121 (Phase II), PHVS416 (on-demand soft capsule, Phase II), and PHVS719 (prophylactic extended-release tablet, Phase I). The company operates across the Netherlands, Switzerland, and the U.S., targeting the high unmet medical need in HAE, a rare and potentially life-threatening genetic disorder. With no approved revenue yet, Pharvaris is strategically positioned in the rapidly growing $3B+ HAE therapeutics market, competing against established players like Takeda and BioCryst. Its pipeline emphasizes oral administration, a key differentiator in a market dominated by injectables, offering potential convenience and improved patient adherence. Investors should note its robust cash position ($280M) supporting clinical development through key milestones.
Pharvaris presents a high-risk, high-reward opportunity in the rare disease therapeutics space. The company’s lead candidate, PHA121, could disrupt the HAE market with its oral administration advantage versus current injectable therapies (e.g., Takeda’s Takhzyro). However, as a pre-revenue biotech, it carries significant clinical and regulatory risks—evidenced by its $100.9M net loss in 2023. The negative beta (-2.85) suggests counter-cyclicality, but volatility is inherent. Key catalysts include Phase II data readouts for PHA121 and PHVS416. With $280M in cash (burn rate: ~$120M/year), the company is funded into 2025, mitigating near-term dilution risk. Investors should weigh its first-mover potential in oral HAE therapies against the competitive threat from BioCryst’s Orladeyo (oral prophylactic) and pipeline candidates from CSL Behring.
Pharvaris’ competitive edge lies in its oral bradykinin B2-receptor antagonists, addressing critical pain points in HAE treatment: the inconvenience of frequent injections and the need for rapid-onset alternatives. Current market leaders (Takeda, CSL Behring) dominate with subcutaneous/infusion therapies, creating a whitespace for Pharvaris’ PHVS416 (on-demand oral) and PHVS719 (prophylactic oral). However, BioCryst’s Orladeyo (oral kallikrein inhibitor) already holds a first-mover advantage in oral prophylaxis, with $350M+ annual sales. Pharvaris must demonstrate superior efficacy/safety to displace entrenched options. Its small-molecule approach may offer cost and scalability benefits over monoclonal antibodies (e.g., Ionis’ donidalorsen). The company’s Netherlands base provides R&D cost efficiencies but complicates U.S. commercialization—likely necessitating a partnership. Competitive risks include CSL’s garadacimab (Phase III) and Intellia’s gene-editing therapies, which could render pharmacological treatments obsolete long-term. Pharvaris’ narrow focus on HAE limits diversification but enhances therapeutic expertise.